Early bird discount available until June 30th
Save $200!

August 21-23, 2014
Santa Clara Hyatt Regency Hotel, Santa Clara, CA

Developing Emerging Regenerative Medicine Solutions for the Diseases of Aging through Industry Collaboration

What will you be discussing?

- Building a rejuvenation biotechnology industry
- Molecular and cellular damage as the cause of the diseases of aging
- Working toward a new investment paradigm, from the research lab to the market
- The economic impact of an aging population on the healthcare system
- Applying a damage repair paradigm to developing therapies for the diseases of aging
- Specialist therapeutic focus areas: Alzheimer’s, oncology, cardiovascular disease, diabetes, musculoskeletal medicine

Introducing your expert speaker faculty:

Julie Allickson  
Wake Forest Institute for Regenerative Medicine

Julie Andersen  
Buck Institute for Research on Aging

Richard Barker  
Center for the Advancement of Sustainable Medical Innovation

Ashley Bush  
Harvard Medical School

Judith Campisi  
Buck Institute for Research on Aging

Guillermo Garcia Cardena  
Harvard Medical School

Christy Carter  
University of Florida

George Church  
Harvard and MIT

Bob Clay  
Kinapse & Highbury Regulatory Science

Rachelle Doody  
Baylor College of Medicine

Laura Esserman  
University of California, San Francisco

Caleb Finch  
USC Davis School of Gerontology

Gabor Forgacs  
Organovo

Howard Fayot  
Viacyte, Inc.

Dana Goldman  
University of Southern California

Claudia Gravekamp  
Albert Einstein College of Medicine

Chris Hornsby  
Risk Management Solutions, Inc.

Jean Hébert  
Albert Einstein College of Medicine

W. Gray Jerome  
Vanderbilt University Medical Center

Jeffrey Karp  
Brigham and Women’s Hospital

Daniel Kraft  
Stanford University

Neil Littman  
California Institute for Regenerative Medicine

Jeanne Loring  
Scripps Research Institute

Linda Marban  
Capricor Therapeutics

Stephen Minger  
GE Healthcare Life Sciences, UK

Peter Nakada  
Risk Management Solutions, Inc.

Brock Reeve  
Harvard Stem Cell Institute

Camilo Ricordi  
University of Miami

Ajay Royan  
Mithril Capital

David Schaffer  
University of California, Berkeley

Dale Schenk  
Prothena Corporation

Michael Sherratt  
University of Manchester

Bernard Siegel  
Genetics Policy Institute

Eric Siemers  
Eli Lilly

Einar M. Sigurdsson  
New York University

Evan Snyder  
Sanford-Burnham Medical Research Institute

Michael West  
Biotime, Inc.

Claude Wischik  
TauRX Therapeutics, Ltd.

James Yoo  
Wake Forest Institute for Regenerative Medicine

REGISTER NOW
PHONE: 650.938.6100  EMAIL: Nicola.Ambler@sens.org  WEB: www.sens.org/rb2014/register
I would like to start by articulating our overarching goal here. At SENS Research Foundation we have a vision of creating a rejuvenation biotechnology industry, the aim of which is to accelerate drug development through an unprecedentedly broad-based collaboration of damage-repair expertise.

Why? Well, it's clear to us all that the prevalence of age-related diseases is spiralling and the socioeconomic impacts are a constant source of concern. Consequently, interest in preventing such diseases through novel approaches to drug development is at an all-time high – but it can be a slow and laborious process. I believe that collaboration from therapeutic area specialists, particularly in the damage repair fields, is crucial to changing the shape of the industry and, ultimately, improving and saving lives.

The Rejuvenation Biotechnology: Emerging Regenerative Medicine Solutions for the Diseases of Aging conference is the latest SENS Research Foundation meeting and will be held on August 21-23 at the Hyatt Regency Santa Clara in Santa Clara, California. I would love to welcome you to this ground-breaking gathering of the growing rejuvenation biotechnology industry, to discuss combinatorial, preventative strategies and to progress treatment for the diseases and disabilities of old age.

In order to make real change, we need to engage with all the stakeholders of the rejuvenation biotech world, which is why our meeting is unique in the sense that it brings together experts from research, academia, industry, policy, finance and regulatory fields.

Please peruse the meeting agenda and register your place – remember, there is a $200 saving until June 30th!

I look forward to seeing you in Santa Clara.

With best wishes,

Aubrey de Grey
Co-Founder and Chief Science Officer
SENS Research Foundation

About the

At SENS Research Foundation, we believe that a world free of age-related disease is possible. That’s why we’re funding work at universities across the world and at our own Research Center in Mountain View, CA.

Our research emphasizes the application of regenerative medicine to age-related disease, with the intent of repairing underlying damage to the body’s tissues, cells, and molecules. Our goal is to help build the industry that will cure the diseases of aging.

SRF is, at its core, a research-focused outreach organization. Our outreach efforts include the biennial SENS conferences at Cambridge, summits, speaking engagements, and general advocacy. We strive to inform policymakers and the public at large about the promise of the damage-repair approach to treating age-related disease.

Register Now
PHONE: 650.938.6100  EMAIL: Nicola.Ambler@sens.org  WEB: www.sens.org/rb2014/register
8:00 am  Registration & Networking Breakfast
9:00 am  Opening Remarks - Michael Kope, CEO, SENS Research Foundation
9:30 am  Keynote: George Church, Professor of Genetics, Harvard Medical School, Professor of Health Sciences and Technology, Harvard and MIT

10:30 am  Molecular and Cellular Damage as the Cause of the Diseases of Aging Panel
This panel will discuss the idea that the diseases of aging may stem from molecular and cellular damage that accrues with age. Topics of discussion will include the types of damage that may be involved, examples of how this applies to one or more diseases, and thoughts on how basic research and industry could use this concept to drive therapeutic target identification and drug/treatment development.

- Richard Barker, Director, Center for the Advancement of Sustainable Medical Innovation: (Moderator)
- Aubrey de Grey, Co-Founder and Chief Science Officer, SENS Research Foundation
- Caleb Finch, ARCO/Kieschnick Professor of Gerontology and Biological Science and University Professor, USC Davis School of Gerontology
- Jeff Karp, Associate Professor, Harvard Medical School, Co-Director of the Center for Regenerative Therapeutics, Brigham and Women’s Hospital
- Stephen Minger, Chief Scientist, Cellular Sciences, GE Healthcare Life Sciences, UK

12:00 pm  Networking Lunch
1:00 pm  CONCURRENT SESSIONS. PLEASE CHOOSE ONE:

Alzheimer’s Disease Session 1
This session will highlight two types of cellular and molecular damage currently being targeted as therapeutic targets for Alzheimer’s Disease. How tau tangles and cell loss are believed to lead to Alzheimer’s Disease, current ideas on how to remove or repair tau tangles, and how cell replacement can be used to treat Alzheimer’s Disease will be discussed.

- Jean Hébert, Professor, Departments of Neuroscience and Genetics, Albert Einstein College of Medicine
- Einar Sigurdsson, Associate Professor, Department of Neuroscience & Physiology, New York University
- Claude Wischik, Professor of Old Age Psychiatry, University of Aberdeen, Scotland; Executive Chairman, TauRX Therapeutics, Ltd.

Cardiovascular Disease Session 1
Building upon the idea discussed by the morning panel of using damage repair therapeutics to treat the diseases of aging, this session will consider cellular and molecular damage that can be targeted for cardiovascular disease therapy. Presentations will explain how cellular or molecular damage may lead to cardiovascular disease and how this damage may be removed, repaired, or replaced.

- Guillermo Garcia Cardena, Associate Professor of Pathology, Harvard Medical School, Director of the Laboratory for Systems Biology, Center for Excellence in Vascular Biology, Brigham and Women's Hospital
- W. Gray Jerome, Associate Professor and Director, Graduate Program in Cellular and Molecular Pathology, Vanderbilt University Medical Center
- Michael Sherratt, Lecturer, Center for Regenerative Medicine, University of Manchester

Toward a New Investment Paradigm Panel
This panel will discuss the challenges in bringing new and especially preventative therapies to treat the diseases of aging from the research lab to the market. The panel will offer and discuss new investment paradigms that could drive drug and therapeutic development.

- Neil Littman, Business Development Officer, California Institute for Regenerative Medicine
- James O’Neill, Partner, Mithril Capital Management
- Bernard Siegel, Executive Director, Genetics Policy Institute
- Michael West, CEO, BioTime, Inc.
2:30 pm  CONCURRENT SESSIONS. PLEASE CHOOSE ONE:

Alzheimer’s Disease Session 2
A third type of damage being targeted for Alzheimer’s therapeutics, A-beta aggregates, will be discussed during this session. How A-beta aggregates are believed to lead to Alzheimer’s Disease and current ideas on how to prevent or remove A-beta aggregates will be considered. This session will also discuss how changing the way researchers, regulators, and pharmaceutical companies view the disease will change Alzheimer’s Disease drug development. Particular attention will be paid to the Accelerate Cure/Treatments for Alzheimer’s Disease (ACT-AD) proposal and recent guidance from the FDA.

- **Ashley Bush**, Head of the Oxidation Disorders Laboratory, Mental Health Research Institute, University of Melbourne, Director of the Laboratory for Oxidation Biology Genetics and Aging Unit, Massachusetts General Hospital, Associate Professor, Department of Psychiatry, Harvard Medical School
- **Rachelle Doody**, Professor of Neurology, Director, Alzheimer’s Disease and Memory Disorders Center, Baylor College of Medicine
- **Eric Siemers**, Medical Director, Alzheimer’s Disease Team, El El Lilly

Cardiovascular Disease Session 2
In this session, examples of current pharmaceutical advances in cardiovascular disease therapeutics will be presented. How these therapeutics remove, repair, or replace molecular and cellular damage and, in doing so, delay or prevent cardiovascular disease will be considered.

- **Gabor Forgacs**, Professor, Biophysics Laboratory, Department of Physics & Astronomy, University of Missouri-Columbia, Founder, Organovo
- **Linda Marban**, CEO, Capricor Therapeutics

The Economic Impact of an Aging Population on the Healthcare System Panel
This panel will discuss the impending economic crisis the healthcare system will soon face caring for the ever-growing elderly population and possible solutions to this crisis, such as an outcomes-based healthcare model.

- **Dana Goldman**, Leonard D. Schaeffer Chair and Director of the Schaeffer Center for Health Policy and Economics, University of Southern California
- **Peter Nakada**, Managing Director of Risk Markets, Risk Management Solutions, Inc.

4:00 pm  Afternoon Break

4:30 pm  Advancing Regenerative Therapies in Alzheimer’s and Cardiovascular Disease Panel
This panel will bring together speakers from sessions throughout the day to consider the promise of a damage repair strategy to develop therapeutics for the diseases of aging. Discussion will include a summary of the accomplishments of the Alzheimer’s community in suggesting an innovative drug development strategy as well as debate about how such a strategy could apply to cardiovascular therapies. In particular, the panel will consider the impact applying a strategy similar to the ACT-AD proposal would have on cardiovascular disease therapeutic development, investment in cardiovascular drug development, and the healthcare system.

- **Aubrey de Grey**, CSO, SENS Research Foundation: (Moderator)
- **Rachelle Doody**, Professor of Neurology, Director, Alzheimer’s Disease and Memory Disorders Center, Baylor College of Medicine
- **Dana Goldman**, Leonard D. Schaeffer Chair and Director of the Schaeffer Center for Health Policy and Economics, University of Southern California
- **Neil Littman**, Business Development Officer, California Institute for Regenerative Medicine
- **Linda Marban**, CEO, Capricor Therapeutics
- **Eric Siemers**, Medical Director, Alzheimer’s Disease Team, El El Lilly

6:00 pm  Poster Session/ Buffet Dinner

8:00 pm  Performance by Comedian Hal Sparks
Currently starring in the Disney XD show, LAB RATS, actor/comedian Hal Sparks began his professional career as a teenager in Chicago. As a member of the famed Second City Troupe, his quick wit and affable personality quickly gained him recognition and acclaim and he was named the “Funniest Teenager In Chicago” by the Chicago Sun Times. Sparks went on to host the Emmy Award- winning “Talk Soup” on E! Entertainment Television, winning rave reviews from fans and critics alike. He starred for five seasons on Showtime’s hit series “Queer As Folk” and appeared in the films “Extract,” “Spiderman 2” and “Dude, Where’s My Car?” Sparks recently starred in his own one hour Showtime comedy special, “Charmageddon,” which is now a best-selling DVD. He is a star commentator on VH1’s popular “I Love the 80’s” series and can be hear every Wednesday on the nationally syndicated “Stephanie Miller Radio Show.” Hal is also a pop culture expert and regularly appears on such shows as “Joy Behar” and CNN’s “Your Money.” His numerous other television appearances include “The Tonight Show,” “Larry King Live,” “Charlie Rose,” “Good Morning America,” “The View,” “Jimmy Kimmel” and MTV. In addition to a busy acting and stand-up career, he is an accomplished musician. Hal and his band, Zero 1, recently released their debut album.
Conference Day 2: Friday August 22, 2014

8:00 am  Registration & Networking Breakfast

9:00 am  Opening Remarks by Edward James Olmos, Actor

9:30 am  Keynote: Ajay Royan, Co-Founder and Managing Director, Mithril

10:30 am  Toward a New Research Paradigm Panel

This panel will explore new ways to approach research to tackle the diseases of aging. In particular, consideration will be given to the effect a damage repair paradigm would have on developing new strategies to identify and study therapeutic targets, fostering more collaboration between researchers studying different diseases, and changing the way translational research and drug development are approached.

- Julie Allickson, Director, Translational Research, Wake Forest Institute for Regenerative Medicine
- Judith Campisi, Professor, Buck Institute for Research on Aging
- Howard Foyt, Vice President, Clinical Development and Chief Medical Officer, ViaCyte, Inc
- Daniel Kraft, Professor, Stanford University

12:00 pm  Networking Lunch

1:00 pm  CONCURRENT SESSIONS. PLEASE CHOOSE ONE:

**Cancer Session**
This session will highlight current breakthroughs in cancer research. Additionally, the impact the I-SPY TRIAL 2 (Investigation of Serial studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2) program has had on drug development, particularly Alzheimer's drugs, will be discussed.

- Judith Campisi, Professor, Buck Institute for Research on Aging
- Laura Esserman, Professor, Departments of Surgery and Radiology, and Affiliate Faculty, Institute for Health Policy Studies and Director, Carol Franc Buck Breast Care Center; Co-Leader, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco
- Claudia Gravekamp, Associate Professor, Albert Einstein College of Medicine

**Parkinson’s Disease Session**
This session will feature the latest in Parkinson’s Disease research. A causal relationship between molecular and/or cellular damage and Parkinson’s Disease will be explored. How the research could lead to preventative or damage repair treatment of the disease will also be considered.

- Julie Andersen, Professor, Buck Institute for Research on Aging
- Jeanne Loring, Professor, Scripps Research Institute
- Dale Schenk, CEO, Prothena Corporation

**Risk-Benefit Analysis in Therapies for the Diseases and Disabilities of Aging**

Today, the translation of healthcare innovations into patient outcomes is an inherently multi-stakeholder effort. Consequently, there is a major need to maintain rigor and independence in the regulation of healthcare innovations, while improving regulatory transparency and opportunities for multi-stakeholder input to accommodate fundamental changes in the life-science ecosystem and global healthcare demands. A key strategy in this endeavor is the development and utilization of novel risk-benefit appraisal methodologies, leveraging advanced in patient reported outcomes (PROMS), stratified medicines – including 'big data' and risk management methodologies utilized presently in other industries.

- Richard Barker, Director, Center for the Advancement of Sustainable Medical Innovation
- David Brindley, Research Fellow, University of Oxford/Center for the Advancement of Sustainable Medical Innovation
- Chris Hornsby, Head of Model Development, Life Risks, Risk Management Solutions, Inc.
- Brock Reeve, Executive Director, Harvard Stem Cell Institute

REGISTER NOW
PHONE: 650.938.6100  EMAIL: Nicola.Ambler@sens.org  WEB: www.sens.org/rb2014/register
3:30 pm **Advancing Regenerative Therapies in Cancer and Parkinson's Disease Panel**
This panel will bring together speakers from throughout the day to summarize the impact of the I-SPY TRIAL 2 program on drug trial design for Alzheimer's therapeutics and speculate on the applicability of trial designs similar to the one proposed for Alzheimer's Disease to the development of therapeutics for other diseases of aging, such as Parkinson's Disease.

- **Aubrey de Grey**, CSO, SENS Research Foundation: (Moderator)
- **Rachelle Doody**, Professor of Neurology, Director, Alzheimer's Disease and Memory Disorders Center, Baylor College of Medicine
- **Laura Esserman**, Professor, Departments of Surgery and Radiology, and Affiliate Faculty, Institute for Health Policy Studies and Director, Carol Franc Buck Breast Care Center; Co-Leader, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco
- **Jeanne Loring**, Professor, Scripps Research Institute
- **Brock Reeve**, Executive Director, Harvard Stem Cell Institute
- **Dale Schenk**, CEO, Prothena Corporation

5:30 pm **Networking Dinner/ Poster Session/ Exhibits**

8:00 pm **Concert by Cecilia Noël**
Originally from Lima, Perú, Noël’s career began at the age of eight with a starring role in a Peruvian television show. As a teenager, Noël’s mother sent her to Argentina and Germany to take voice, violin, and piano lessons. Encouraged by the legendary Stan Getz to move to the US, Noël relocated to New York City and briefly performed as a dancer with Jo Jo’s Dance Factory and Menudo. Noël moved to Los Angeles in 1989 and in the early 1990s formed Cecilia Noël and The Wild Clams. The group received quick attention for their explosive live shows and were consequently booked at the House of Blues and the Playboy Jazz Festival. Critics have long called her the “Latin Tina Turner.” “Salsoul”, the genre Noël created to describe her sound, combines elements of salsa, soul, jazz, funk, and Afro-cuban. Noël also performs and records with husband and former Men At Work frontman Colin Hay.

---

**Conference Day 3: Saturday August 23, 2014**

8:00 am Networking Breakfast

9:00 am Keynote: TBD

10:00 am **Applying a Damage Repair Paradigm to Developing Therapies for the Diseases of Aging Panel**
Building upon the discussion of a damage repair paradigm from days 1 and 2, this panel will weigh the benefits of application of a damage repair paradigm to drug development to combat the diseases of aging. Discussion will include the feasibility of applying such a strategy, the advantages and disadvantages such a model would confer, and an analysis of the regulatory changes that would be required to make such a paradigm possible.

- **Julie Allickson**, Director, Translational Research, Wake Forest Institute for Regenerative Medicine
- **Richard Barker**, Director, Center for the Advancement of Sustainable Medical Innovation: (Moderator)
- **Stephen Minger**, Chief Scientist, Cellular Sciences, GE Healthcare Life Sciences, UK

11:30 am Networking Lunch
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30 pm</td>
<td>CONCURRENT SESSIONS. PLEASE CHOOSE ONE:</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>Musculoskeletal Disease Session</td>
</tr>
<tr>
<td></td>
<td>This session will highlight current musculoskeletal disease research.</td>
</tr>
<tr>
<td></td>
<td>Presenters will discuss how molecular or cellular damage is believed</td>
</tr>
<tr>
<td></td>
<td>to lead to their musculoskeletal disease of interest and how their</td>
</tr>
<tr>
<td></td>
<td>research may contribute to delaying or preventing the disease.</td>
</tr>
<tr>
<td></td>
<td>• Christy Carter, Assistant Professor, Department of Aging and Geriatric</td>
</tr>
<tr>
<td></td>
<td>Research, Institute on Aging, University of Florida</td>
</tr>
<tr>
<td></td>
<td>• David Schaffer, Professor, University of California, Berkeley, Director,</td>
</tr>
<tr>
<td></td>
<td>Berkeley Stem Cell Center</td>
</tr>
<tr>
<td>1:30 pm</td>
<td>Break</td>
</tr>
<tr>
<td>2:00 pm</td>
<td>Advancing Regenerative Therapies in Musculoskeletal Disease and Diabetes</td>
</tr>
<tr>
<td></td>
<td>Panel</td>
</tr>
<tr>
<td></td>
<td>This panel will bring together speakers from throughout the day to</td>
</tr>
<tr>
<td></td>
<td>consider the possibility of applying a drug trial design similar to</td>
</tr>
<tr>
<td></td>
<td>the ones emerging from the Alzheimer’s Disease and cancer communities.</td>
</tr>
<tr>
<td></td>
<td>The feasibility of applying such a model will be considered with the</td>
</tr>
<tr>
<td></td>
<td>biology of the disease, regulatory concerns, and pharmaceutical needs</td>
</tr>
<tr>
<td></td>
<td>in mind.</td>
</tr>
<tr>
<td></td>
<td>• Christy Carter, Assistant Professor, Department of Aging and Geriatric</td>
</tr>
<tr>
<td></td>
<td>Research, Institute on Aging, University of Florida</td>
</tr>
<tr>
<td></td>
<td>• Aubrey de Grey, CSO, SENS Research Foundation: (Moderator)</td>
</tr>
<tr>
<td></td>
<td>• Andrew Martello, Managing Director, Spoonful of Sugar Adherence</td>
</tr>
<tr>
<td></td>
<td>• Camillo Ricordi, Stacy Joy Goodman Professor of Surgery, Distinguished</td>
</tr>
<tr>
<td></td>
<td>Professor of Medicine, Director, Diabetes Research Institute and Cell</td>
</tr>
<tr>
<td></td>
<td>Transplant Program, University of Miami</td>
</tr>
<tr>
<td></td>
<td>• James Yoo, Professor and Assistant Director, Wake Forest Institute for</td>
</tr>
<tr>
<td></td>
<td>Regenerative Medicine</td>
</tr>
<tr>
<td>3:00 pm</td>
<td>Building a Rejuvenation Biotechnology Industry</td>
</tr>
<tr>
<td></td>
<td>This panel will synthesize the discussion from all of the conference</td>
</tr>
<tr>
<td></td>
<td>sessions and panels. A cross-section of academics, pharmaceutical</td>
</tr>
<tr>
<td></td>
<td>reps, policy makers, and other presenters will revisit the merits of a</td>
</tr>
<tr>
<td></td>
<td>damage repair paradigm to address the diseases of aging considered at</td>
</tr>
<tr>
<td></td>
<td>this conference. Panelists will consider the changes that would be</td>
</tr>
<tr>
<td></td>
<td>required to lay the groundwork for a new industry perspective</td>
</tr>
<tr>
<td></td>
<td>focused on addressing damage indications for the diseases of aging</td>
</tr>
<tr>
<td></td>
<td>either through preventing or repairing such damage.</td>
</tr>
<tr>
<td></td>
<td>• George Church, Professor of Genetics, Harvard Medical School, Professor</td>
</tr>
<tr>
<td></td>
<td>of Health Sciences and Technology, Harvard and MIT</td>
</tr>
<tr>
<td></td>
<td>• Dana Goldman, Leonard D. Schaeffer Chair and Director of the Schaeffer</td>
</tr>
<tr>
<td></td>
<td>Center for Health Policy and Economics, University of Southern California</td>
</tr>
<tr>
<td></td>
<td>• Michael Kope, CEO, SENS Research Foundation: (Moderator)</td>
</tr>
<tr>
<td></td>
<td>• Neil Litman, Business Development Officer, California Institute for</td>
</tr>
<tr>
<td></td>
<td>Regenerative Medicine</td>
</tr>
<tr>
<td></td>
<td>• Stephen Minger, Chief Scientist, Cellular Sciences, GE Healthcare Life</td>
</tr>
<tr>
<td></td>
<td>Sciences, UK</td>
</tr>
<tr>
<td></td>
<td>• Brock Reeve, Executive Director, Harvard Stem Cell Institute</td>
</tr>
<tr>
<td>4:30 pm</td>
<td>Conference Concludes</td>
</tr>
</tbody>
</table>

**Diabetes Session**

Breakthroughs in diabetes research will be presented in this session. The molecular and cellular causes of diabetes will be considered and strategies to remove, repair, or replace such damage will be discussed.

- Camillo Ricordi, Stacy Joy Goodman Professor of Surgery, Distinguished Professor of Medicine, Director, Diabetes Research Institute and Cell Transplant Program, University of Miami
- James Yoo, Professor and Assistant Director, Wake Forest Institute for Regenerative Medicine

**Regulating a Damage Repair Approach to Cure the Diseases of Aging Panel**

Escalating societal healthcare needs have driven an unprecedented era of biomedical innovation. However, the development of candidate technologies without consideration of a robust regulatory strategy is likely to contribute to stymied patient access and commercial viability. Therefore, this session will consider worldwide efforts to rapidly and proportionally develop international regulatory processes to accommodate increasingly heterogeneous and unfamiliar healthcare technologies and their swift translation from lab to bedside.

- David Brindley, Research Fellow, University of Oxford/Center for the Advancement of Sustainable Medical Innovation: (Moderator)
- Bob Clay, Chief Regulatory Officer, Kinapse & Managing Director, Highbury Regulatory Science
- Andrew Martello, Managing Director, Spoonful of Sugar Adherence
- Evan Snyder, Director, Center for Stem Cell and Regenerative Medicine, Director, Stem Cell Research Center and Core Facility, Sanford-Burnham Medical Research Institute

**REGISTER NOW**

PHONE: 650.938.6100  EMAIL: Nicola.Ambler@sens.org  WEB: www.sens.org/rb2014/register
SRF’s inaugural Rejuvenation Biotechnology Conference provides the only platform for the age-related disease world to come together and shape its own community. Nowhere else will you find all of the crucial stakeholders that drive progression in rejuvenation biotechnology.

Experts from across several aging disease fields, regulatory experts, investment, policy, and disease advocacy, and investors will join the expert speaker panel to discuss the future of rejuvenation biotechnology.

Sponsoring the Rejuvenation Biotechnology Conference is an easy and affordable way to promote your program, products, or institution to a targeted professional audience while supporting the continued development of the Rejuvenation Biotechnology field.

There are a wide variety of sponsorship packages and options that can be tailored to your individual needs.

For more information, please contact Jerri Barrett: jerri.barrett@sens.org

RB 2014 Sponsors:

Life Extension®
Foundation for Longer Life

Sierra Sciences

REGENERATIVE MEDICINE FOUNDATION

GPI.

PEPROTECH
Manufacturer of Quality Cytokine Products

BIOWATCH
Your independent Biotech News Source

REGISTER NOW
PHONE: 650.938.6100  EMAIL: Nicola.Ambler@sens.org  WEB: www.sens.org/rb2014/register
Pricing

<table>
<thead>
<tr>
<th></th>
<th>EARLY BIRD (expires 30th June)</th>
<th>Standard Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Students</td>
<td>$595</td>
<td>$795</td>
</tr>
<tr>
<td>Academics</td>
<td>$995</td>
<td>$1195</td>
</tr>
<tr>
<td>Industry/Gov/General Public</td>
<td>$1795</td>
<td>$1995</td>
</tr>
</tbody>
</table>

Conference Registration Includes:

- Full access to all sessions
- Full access to Poster Session
- Special Entertainment and dinners on Thursday and Friday Evenings
- Continental Breakfast
- PM Refreshment Breaks
- Lunch

Click here to register for the conference.

Early bird discount available until June 30th
Save $200!

Travel and Hotel Information

The Rejuvenation Biotechnology Conference will be held at the Hyatt Regency Santa Clara Hotel. A limited number of rooms have been reserved for the Rejuvenation Biotechnology Conference at the discounted rate of $199 per night. Book your reservation today.

The Hyatt Regency Santa Clara Hotel is conveniently located near both the San Francisco International Airport (SFO) and Norman Y. Mineta San Jose International Airport (SJC).

The Hyatt Regency Santa Clara Hotel is the ultimate in convenience and Four Diamond excellence. Located in the heart of Silicon Valley, the Hyatt Regency is a luxury Bay Area hotel attached to the Convention Center, right across the street from California’s Great America Theme Park and next to the new Levi’s Stadium, home of the 49ers.

Hyatt Regency Santa Clara
5101 Great America Parkway
Santa Clara, California, USA, 95054
Tel: +1 408 200 1234

Map and Directions

To receive the Rejuvenation Biotechnology Conference special rate click here for your reservation.